Two new biomarkers, mesothelin and HE4, for diagnosis of ovarian carcinoma

Bibliography

• Jemal A, Siegel R, Ward E, Cancer statistics, 2009. CA Cancer J Clin 2009;59:225-49
   PubMed Web of Science ®Google Scholar
• Kobel M, Kalloger SE, Boyd N, Ovarian carcinoma subtypes are different diseases: implications for biomarker studies. PLOS Med 2008;5:e232
   PubMed Web of Science ®Google Scholar
• Brown PO, Palmer C. The preclinical natural history of serous ovarian cancer: defining the target for early detection. PLOS Med 2009;6:e1000114
   PubMed Web of Science ®Google Scholar
• Kobel M, Kalloger SE, Huntsman DG, Differences in tumor type in low-stage versushigh-stage ovarian carcinoma. Int J Gynecol Pathol 2010;29:201-11
   Google Scholar
• Crum CP. Intercepting pelvic cancer in the distal fallopian tube: theories and realities. Mol Oncol 2009;3:165-70
   PubMed Web of Science ®Google Scholar
• Kobel M, Kalloger SE, Santos JL, Tumor type and substage predict survival in stage I and II ovarian carcinoma: insights and implications. Gynecol Oncol 2010;116:50-6
   PubMed Web of Science ®Google Scholar
• Mackay HJ, Brady MF, Oza AM, Prognostic relevance of uncommon ovarian histology in women with stage III/IV epithelial ovarian cancer. Int J Gynecol Cancer 2010;20:945-52
   PubMed Web of Science ®Google Scholar
• Etzioni R, Urban N, Ramsey S, The case for early detection. Nat Rev Cancer 2003;3:243-52
   PubMed Web of Science ®Google Scholar
• Bast RC Jr, Feeney M, Lazarus H, Reactivity of a monoclonal antibody with human ovarian carcinoma. J Clin Invest 1981;68:1331-7
   PubMed Web of Science ®Google Scholar
• Einhorn N, Sjovall K, Knapp RC, Prospective evaluation of serum CA125 levels for early detection of ovarian cancer. Obstet Gynecol 1992;80:14-8
   PubMed Web of Science ®Google Scholar
• Skates SJ, Menon U, MacDonald N, Calculation of the risk of ovarian cancer from serial CA-125 values for preclinical detection in postmenopausal women. J Clin Oncol 2003;21:206-10
   PubMedGoogle Scholar
• Jacobs I, Bast RC. The CA-125 tumour associated antigen: a review of the literature. Hum Repro 1989;4:1-12
   PubMed Web of Science ®Google Scholar
• Jacobs I, Stabile I, Bridges J, Multimodal approach to screening for ovarian cancer. Lancet 1999;353:1207-10
   PubMed Web of Science ®Google Scholar
• Berek JS, Bast RC Jr. Ovarian cancer screening. The use of serial complementary tumor markers to improve sensitivity and specificity for early detection. Cancer 1995;76:2092-6
   PubMed Web of Science ®Google Scholar
• Maggino T, Gadducci A, D'Addario V, Prospective multicenter study on CA 125 in postmenopausal pelvic masses. Gynecol Oncol 1994;54:117-23
   PubMed Web of Science ®Google Scholar
• Fung MF, Bryson P, Johnston M, Chambers A. Cancer care ontario practice guidelines initiative gynecology cancer disease site group. Screening postmenopausal women for ovarian cancer: a systematic review. J Obstet Gynaecol Can 2004;26:717-28
   PubMedGoogle Scholar
• Sato S, Yokoyama Y, Sakamoto T, Usefulness of mass screening for ovarian carcinoma using transvaginal ultrasonography. Cancer 2000;89:585-8
   Google Scholar
• Rosenthal AN, Jacobs IJ. The role of CA125 in screening for ovarian cancer. Int J Biol Markers 1998;13:651-8
   Google Scholar
• Kozak KR, Amneus MW, Pusey SM, Identification of biomarkers for ovarian cancer using strong anion-exchange proteinchips: potential use in diagnosis and prognosis. Proc Natl Acad Sci USA 2003;100:12343-8
   PubMed Web of Science ®Google Scholar
• Su F, Lang JH, Kumar A, Validation of candidate serum ovarian cancer biomarkers for early detection. Biomark Insights 2007;2:369-75
   PubMedGoogle Scholar
• Nosov V, Su F, Amneus M, Validation of serum biomarkers for detection of early-stage ovarian cancer. Am J Obstet Gynecol 2009;200(6): 639,e1-5
   PubMed Web of Science ®Google Scholar
• Rosen DG, Wang L, Atkinson JN, Potential markers that complement expression of CA125 in epithelial ovarian cancer. Gynecol Oncol 2005;99:267-77
   PubMed Web of Science ®Google Scholar
• Li L, Dowdy S, Tipton T, HE4 as a biomarker for ovarian and endometrial cancer management. Expert Rev Mol Diagn 2009;9:555-66
   PubMed Web of Science ®Google Scholar
• Scholler N, Fu N, Yang Y, Soluble member(s) of the mesothelin/megakaryocyte potentiating factor family are detectable in sera from patients with ovarian carcinoma. Proc Natl Acad Sci USA 1999;96:11531-6
   PubMed Web of Science ®Google Scholar
• Chang K, Pai LH, Batra JK, Characterization of the antigen (CAK1) recognized by monoclonal antibody K1 present on ovarian cancers and normal mesothelium. Cancer Res 1992;52:181-6
   PubMed Web of Science ®Google Scholar
• Chang K, Pastan I. Molecular cloning and expression of a cDNA encoding a protein detected by the K1 antibody from an ovarian carcinoma (OVCAR-3) cell line. Int J Cancer 1994;57:90-7
   PubMed Web of Science ®Google Scholar
• Chang K, Pastan I. Molecular cloning of mesothelin, a differentiation antigen present on mesothelium, mesotheliomas, and ovarian cancers. Proc Natl Acad Sci USA 1996;93:136-40
   PubMed Web of Science ®Google Scholar
• Kojima T, Oh-eda M, Hattori K, Molecular cloning and expression of megakaryocyte potentiating factor cDNA. J Biol Chem 1995;270:21984-90
   PubMed Web of Science ®Google Scholar
• Rump A, Morikawa Y, Tanaka M, Binding of ovarian cancer antigen CA125/MUC16 to mesothelin mediates cell adhesion. J Biol Chem 2004;279:9190-8
   PubMed Web of Science ®Google Scholar
• Hellstrom I, Raycraft J, Kanan S, Mesothelin-variant 1 is released from tumor cells as a diagnostic marker. Cancer Epidemiol Biomarkers Prev 2006;15:1014-20
   PubMed Web of Science ®Google Scholar
• Muminova ZE, Strong TV, Shaw DR. Characterization of human mesothelin transcripts in ovarian and pancreatic cancer. BMC Cancer 2004;4:19-29
   PubMed Web of Science ®Google Scholar
• McIntosh MW, Drescher C, Karlan B, Combining CA125 and SMR serum markers for diagnosis and early detection of ovarian carcinoma. Gynecol Oncol 2004;95:9-15
   PubMed Web of Science ®Google Scholar
• Beyer HL, Geschwindt RD, Glover CL, MESOMARK (TM): A potential test for malignant pleural mesothelioma. Clinical Chemistry 2007; 534: 666-72
   Google Scholar
• Lowe KA, Shah CA, Wallace E, Effects of personal characteristics on serum CA125, mesothelin and HE4 levels in healthy postmenopausal women at high risk for ovarian cancer. Cancer Epidemiol Biomarkers Prev 2008;17:2480-7
   PubMed Web of Science ®Google Scholar
• Shah CA, Lowe KA, Paley PJ, Influence of ovarian cancer risk status on the diagnostic performance of the serum biomarkers mesothelin, HE4, and CA125. Cancer Epidemiol Biomarker Prev 2009;18:1365-72
   PubMed Web of Science ®Google Scholar
• Moore RG, Brown AK, Miller MC, The use of multiple novel tumor biomarkers for the detection of ovarian carcinoma in patients with a pelvic mass. Gynecol Oncol 2008;108:402-8
   PubMed Web of Science ®Google Scholar
• Ye B, Skates S, Mok SC, Proteomic-based discovery and characterization of glycosylated eosinophil-derived neurotoxin and COOH-terminal osteopontin fragments for ovarian cancer in urine. Clin Cancer Res 2006;12:432-41
   PubMed Web of Science ®Google Scholar
• Badgwell D, Lu Z, Cole L, Urinary mesothelin provides greater sensitivity for early stage ovarian cancer than serum mesothelin, urinary hCG free beta subunit and urinary hCG beta core fragment. Gynecol Oncol 2008;106:490-7
   Web of Science ®Google Scholar
• Robinson BWS, Creaney J, Lake RL, Mesothelin-family proteins and diagnosis of mesothelioma. Lancet 2003;362:1612-16
   PubMed Web of Science ®Google Scholar
• Creaney J, Yeoman D, Naumoff LK, Soluble mesothelin in effusions: a useful tool for the diagnosis of malignant mesothelioma. Thorax 2007;62:569-76
   PubMed Web of Science ®Google Scholar
• Lee YCG. Editorial: hunting for a pleural fluid test for mesothelioma: is soluble mesothelin the answer? Thorax 2007;62:561-2
   PubMed Web of Science ®Google Scholar
• Cristaudo A, Foddis R, Vivaldi A, Clinical significance of serum mesothelin in patients with mesothelioma and lung cancer. Clin Cancer Res 2007;13:5076-81
   PubMed Web of Science ®Google Scholar
• Park E-K, Sandrini A, Yatesd DH, Soluble mesothelin-related protein in an asbestos-exposed population. The dist diseases boad cohort study. Am J Respir Care Med 2008;178:832-7
   PubMed Web of Science ®Google Scholar
• Pass HI, Wali A, Tang N, Soluble mesothelin-related peptide level elevation in mesothelioma serum and pleural effusions. Ann Thorac Surg 2008;85:265-72
   PubMed Web of Science ®Google Scholar
• Davies HE, Sadler RS, Bielsa S, Clinical impact and reliability of pleural fluid mesothelin in undiagnosed pleural effusions. Am J Resdpir Crit Care Med 2009;180:437-44
   PubMed Web of Science ®Google Scholar
• Segawa T, Hagiwara Y, Ishikawa K, MeSOMARK kit detects C-ERC/mesothelin, but not SMRP with C-terminus. Biochem Biophys Res Commun 2008;369:915-8
   PubMed Web of Science ®Google Scholar
• Wheatley-Price P, Yang B, Patsios D, Soluble mesothelin-related peptide and osteopontin as marakers of response in malignant mesothelioma. J Clin Oncol 2010;28:3316-22
   PubMed Web of Science ®Google Scholar
• Creaney J, Olsen NJ, Brims F, Serum mesothelin for early detection of asbestos-induced cancer malignant mesothelioma. Cancer Epidemiol Biomarkers Prev 2010;19:2238-46
   PubMed Web of Science ®Google Scholar
• Johnston FM, Tan MCB, Tan BR Jr, Circulating mesothelin protein and cellular anti-mesothelin immunity in patients with pancreatic cancer. Clin Cancer Res 2009;15:6511-18
   PubMed Web of Science ®Google Scholar
• Dandekar AM, Robinson EA, Appellla E, Quasba PK. Complete sequence analysis of cDNA clones encoding rat whey phosphoprotein: homology to a protease inhibitor. Proc Natl Acad SciUSA 1982;79:3987-91
   PubMed Web of Science ®Google Scholar
• Heinzel R, Appelhans H, Gassen G, Molecular cloning and expression of cDNA for human antileukoprotease from cervix uterus. Eur J Biochem 1986;160:61-7
   PubMed Web of Science ®Google Scholar
• Wiedow O, Schroder JM, Gregory H, Elafin: an elastase-specific inhibitor of human skin. Purification, characterization, and complete amino acid sequence. J Biol Chem 1990;265:14791-5
   PubMed Web of Science ®Google Scholar
• Kirchoff C, Habben I, Ivell R, Krull N. A major human epididymis-specific cDNA encodes a protein with sequence homology to extracellular proteinase inhibitor. Biol Reprod 1991;45:350-7
   PubMed Web of Science ®Google Scholar
• Galgano MT, Hampton GM, Frierson HFJ. Comprehensive analysis of HE4 expression in normal and malignant human tissues. Mod Pathol 2006;19:847-53
   PubMed Web of Science ®Google Scholar
• Schummer M, Ng W, Bumgarner R, Comparative hybridization of an array of 21 500 ovarian cDNAs for the discovery of genes overexpressed in ovarian carcinomas. Gene 1999;238:375-85
   PubMed Web of Science ®Google Scholar
• Wang K, Gan L, Jeffrey E, Monitoring gene expression profile changes in ovarian carcinomas using cDNA microarray. Gene 1999;229:101-8
   PubMed Web of Science ®Google Scholar
• Hough CD, Cho K, Zonderman A, Coordinately upregulated genes in ovarian cancer. Cancer Res 2001;61:3869-76
   PubMed Web of Science ®Google Scholar
• Shridhar V, Lee J, Pandita A, Genetic analysis of early- versus late-stage ovarian tumors. Cancer Res 2001;61:5895-904
   PubMed Web of Science ®Google Scholar
• Bingle L, Singleton V, Bingle CD. The putative ovarian tumour marker gene HE4 (WDSC2) is expressed in normal tissues and undergoes complex alternative splicing to yield multiple protein isoforms. Oncogene 2002;21:2768-73
   PubMed Web of Science ®Google Scholar
• Drapkin R, von Horsten H, Lin Y, Human epididymis protein 4 (HE4) is a secreted glycoprotein that is overexpressed by serous and endometroid ovarian carcinomas. Cancer Res 2005;65:2162-9
   PubMed Web of Science ®Google Scholar
• Hough CD, Sherman-Baust CA, Pizer ES, Large-scale serial analysis of gene expression reveals genes differentially expressed in ovarian cancer. Cancer Res 2000;60:6281-7
   PubMed Web of Science ®Google Scholar
• Ono K, Tanaka T, Tsunoda T, Identification by cDNA microarray of genes involved in ovarian carcinogenesis. Cancer Res 2000;60:5007-11
   PubMed Web of Science ®Google Scholar
• Hellstrom I, Raycraft J, Hayden-Ledbetter M, The HE4 (WFDC2) protein is a biomarker for ovarian carcinoma. Cancer Res 2003;63:3695-700
   PubMed Web of Science ®Google Scholar
• Scholler N, Lowe KA, Bergan LA, Use of yeast-secreted in vivo biotinylated recombinant antibodies (Biobodies) in bead-based ELISA. Clin Cancer Res 2008;14:2647-55
   PubMed Web of Science ®Google Scholar
• Havrilesky LJ, Whitehead CM, Rubatt JM, Evaluation of biomarker panels for early stage ovarian cancer detection and monitoring for disease recurrence. Gynecol Oncol 2008;110:374-82
   PubMed Web of Science ®Google Scholar
• Paulsen T, Kjaerheim K, Kaern J, Improved short-term survival for advanced ovarian, tubal, and peritoneal cancer patients operated at teaching hospitals. Int J Gynecol Cancer 2006;16:11-17
   PubMed Web of Science ®Google Scholar
• Moore RG, McMeekin DS, Brown A.K, A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic mass. Gynecol Oncol 2009;112:40-6
   PubMed Web of Science ®Google Scholar
• Montagnana M, Lippi G, Ruzzenente O, The utility of serum human epididymis protein 4 (HE4) in patients with a pelvic mass. J Clin Lab Anal 2009;23:331-5
   PubMed Web of Science ®Google Scholar
• Palmer C, Duan X, Hawley S, Systemic evaluation of candidate blood markers for detecting ovarian cancer. PLOS One 2008;3:e2633
   PubMed Web of Science ®Google Scholar
• Huhtinen K, Suvitie P, Hiissa J, Serum HE4 concentrations differentiatesd malignant ovarian tumours from ovarian endometriotic cysts. Brit J Cancer 2009;100:1315-19
   PubMed Web of Science ®Google Scholar
• Abdel-Azeez HA, Labib HA, Sharaf SM, Refaie AN. HE4 and mesothelin: novel biomarkers of ovarian carcinoma with pelvic masses. Asian Pac J Cancer Prev 2010;11:111-16
   PubMed Web of Science ®Google Scholar
• Andersen MR, Goff BA, Lowe KA, Use of a symptom index, CA125 and HE4 to predict ovarian cancer. Gynecol Oncol 2010;116:378-83
   PubMed Web of Science ®Google Scholar
• Nolen B, Velikokhatnaya L, Marrangoni A, Serum biomarker panels for the discremination of benign from malignant cases in patients with an adnexal mass. Gynecol Oncol 2010;117:440-5
   PubMed Web of Science ®Google Scholar
• Anastasi E, Biovanna MG, Viggiani V, HE4: a new potential early biomarker for the recurrence of ovarian cancer. Tumor Biol 2010;31:113-19
   PubMed Web of Science ®Google Scholar
• Yurkovetsky Z, Skates S, Lomakin A, Development of a mutlimarker assay for early detection of ovarian cancer. J Clin Oncol 2010;28:2159-66
   PubMed Web of Science ®Google Scholar
• Anderson GL, McIntosh M, Wu L, Assessing lead time of selected ovarian cancer biomarkers: a nested case-control study. J Nat Cancer Inst 2010;102:26-38
   PubMed Web of Science ®Google Scholar
• Hellstrom I, Heagerty PJ, Swisher EM, Detection of the HE4 prortein in urine as a biomarker for ovarian neoplasms. Cancer Lett 2010;296:43-8
   PubMed Web of Science ®Google Scholar
• Moore RG, Brown AK, Miller MC, Utility of a novel serum tumor biomarker HE4 in patients with endometrioid adenocarcinoma of the uterus. Gynecol Oncol 2008;110:196-201
   PubMed Web of Science ®Google Scholar
• Bingle L, Cross S, High AS, WFDC2 (HE4): a potential role in the innate immunity of the oral cavity and resiratory tract in the development of adenocarcinomas of the lung. Respiratory Res 2006;7:61-80
   PubMed Web of Science ®Google Scholar
• Klein G, Clifford P, Klein E, Stjernsward J. Search for tumor specific immune reactins in Burkitt lymphoma patients by the membrane immunofluorescence reaction. Proc Natl Acad Sci USA 1966;55:1628-35
   PubMed Web of Science ®Google Scholar
• Morton DL, Malmgren RA, Holmes EC, Ketcham A. Demonstration of antibodies against human malignant melanoma by immunofluorescence. Surgery 1968;64:233-40
   PubMed Web of Science ®Google Scholar
• Hellstrom I, Hellstrom KE, Pierce GE, Yang JP. Cellular and humoral immunity to different types of human neoplasms. Nature 1968;220:1352-4
   PubMed Web of Science ®Google Scholar
• Old LJ, Chen YT. New paths in human cancer serology. J Exp Med 1998;187:1163-7
   PubMed Web of Science ®Google Scholar
• Cramer DW, Titus-Ernstoff L, McKolanis JR, Conditions associated with antibodies against the tumor-associated antigen MUC1 and their relationship to risk for ovarian cancer. Cancer Epidemiol Biomarkers Prev 2005;14:1125-31
   PubMed Web of Science ®Google Scholar
• Goodell V, Disis ML. Human tumor cell lysates as a protein source for the detection of cancer antigen-specific humoral immunity. J Immunol Methods 2005;299:129-38
   PubMed Web of Science ®Google Scholar
• Disis ML, Pupa SM, Gralow JR, High-titer HER-2/neu protein-specific antibody can be detected in patients with early-stage breast cancer. J Clin Oncol 1997;15:3363-7
   PubMed Web of Science ®Google Scholar
• Ho MH, Hassan R, Zhang J, Humoral immune response to mesothelin in mesothelioma and ovarian cancer patients. Clin Cancer Res 2005;11:3814-20
   PubMed Web of Science ®Google Scholar
• Hellstrom I, Friedman E, Verch T, Anti-mesothelin antibodies and circulating mesothelin relate to the clinical state in ovarian cancer patients. Cancer Epidemiol Biomarkers Prev 2008;17:1520-6
   PubMed Web of Science ®Google Scholar
• Hellstrom KE, Hellstrom I. Novel approaches to therapeutic cancer vaccines. Expert Rev Vaccines 2003;2:517-32
   PubMedGoogle Scholar
• Hassan R, Bera TK, Pastan I. Mesothelin: a new target for immunothearpy. ClinCancer Res 2004;10:3937-42
   Web of Science ®Google Scholar
• Luborsky JL, Visintin I, Boyers S, Ovarian antibodies detected by immobilized antigen immunoassay in patients with premature ovarian failure. J Clin Endocrinol Metab 1990;70:69-75
   PubMed Web of Science ®Google Scholar
• Luborsky J, Llanes B, Davies S, Ovarian autoimmunity: greater frequency of autoantibodies in premature menopause and unexplained infertility than in the general population. Clin Immunol Immunopathol 1999;90:368-74
   Google Scholar
• Luborsky J. Ovarian autoimmune disease and ovarian autoantibodies. J Womens Health Gend Based Med 2002;11:585-99
   PubMedGoogle Scholar
• Luborsky JL, Barua A, Shatavi SV, Anti-tumor antibodies in ovarian cancer. Am J Reprod Immunol 2005;54:55-62
   PubMed Web of Science ®Google Scholar
• Barua A, Bradaric MJ, Kebede T, Anti-ovarian and anti-tumor antibodies in women with ovarian cancer. Am J Reprod Immunol 2007;57:243-9
   PubMed Web of Science ®Google Scholar
• Brinton LA, Westhoff CL, Scoccia B, Causes of infertility as predictors of subsequent cancer risk. Epidemiology 2005;16:500-7
   PubMed Web of Science ®Google Scholar
• Prehn RT. The immune response as a stimulator of tumor growth. Science 1972;176:170-1
   PubMed Web of Science ®Google Scholar
• Fredrickson T. Ovarian tumors of the hen. Environ Health Perspect 1987;73:35-51
   PubMed Web of Science ®Google Scholar
• Fong MY, Kakar SS. Ovarian cancer mouse models: a summary of current models and their limitations. J Ovarian Res 2009;2:12
   PubMed Web of Science ®Google Scholar
• Roby K, Taylor CCS, JP, Development of a syngeneic mouse model for events related to ovarian cancer. Carcinogenesis 2000;21:585-91
   PubMed Web of Science ®Google Scholar
• Nossov V, Amneus M, Su F, The early detection of ovarian cancer: from traditional methods to proteomics. Can we really do better than serum CA-125? Am J Obstet Gynecol 2008;199:15-23
   Google Scholar
• Kozak KR, Su F, Whitelegge JP, Characterization of serum biomarkers for detection of early stage ovarian cancer. Proteomics 2005;5:4589-96
   PubMed Web of Science ®Google Scholar